Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach

Journal of Medicinal Chemistry

Volumn 59, Issue 9, 2016, Pages 4326-4341

  Xie, Lei ^c,d   Zhao, Zheng ^a   Xie, Li ^b   Bourne, Philip E ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Scripps Ranch   (United States)

^c City University of New York   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; AXITINIB; BOSUTINIB; CABOZANTINIB; CERITINIB; CRIZOTINIB; DABRAFENIB; DASATINIB; ERLOTINIB; GEFITINIB; IBRUTINIB; IDELALISIB; IMATINIB; LAPATINIB; NILOTINIB; NINTEDANIB; PALBOCICLIB; PAZOPANIB; PONATINIB; PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; RUXOLITINIB; SORAFENIB; SUNITINIB; TOFACITINIB; TRAMETINIB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB;

ANALYTIC METHOD; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; FUNCTIONAL SITE INTERACTION FINGERPRINT; HINGE REGION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; NON SMALL CELL LUNG CANCER; POLYPHARMACOLOGY; STRUCTURAL GENOMICS; CHEMISTRY; DRUG DESIGN; PROTEIN DATABASE;

DATABASES, PROTEIN; DRUG DESIGN; HUMANS; POLYPHARMACOLOGY; PROTEIN KINASES;

EID: 84969528890     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b02041     Document Type: Article

References (103)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934 10.1126/science.1075762
2. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051 10.1038/nbt.1990
3. Ward, R. A.; Goldberg, F. Kinase Drug Discovery; RSC Publishing: Cambridge, U.K., 2012.
4. Klebl, B.; Müller, G.; Hamacher, M. Protein Kinase as Drug Targets; Wiley-VCH Verlag GambH & Co. KGaA: Weinheim, Germany, 2011; Vol. 49.
5. Goldman, J. M.; Melo, J. V. Chronic myeloid leukemia - advances in biology and new approaches to treatment N. Engl. J. Med. 2003, 349, 1451-1464 10.1056/NEJMra020777
6. Fedorov, O.; Muller, S.; Knapp, S. The (un)targeted cancer kinome Nat. Chem. Biol. 2010, 6, 166-169 10.1038/nchembio.297
7. Sarnpitak, P.; Mujumdar, P.; Taylor, P.; Cross, M.; Coster, M. J.; Gorse, A. D.; Krasavin, M.; Hofmann, A. Panel docking of small-molecule libraries-Prospects to improve efficiency of lead compound discovery Biotechnol. Adv. 2015, 33, 941-947 10.1016/j.biotechadv.2015.05.006
8. Wu, P.; Nielsen, T. E.; Clausen, M. H. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs Drug Discovery Today 2016, 21, 5-10 10.1016/j.drudis.2015.07.008
9. Muller, S.; Chaikuad, A.; Gray, N. S.; Knapp, S. The ins and outs of selective kinase inhibitor development Nat. Chem. Biol. 2015, 11, 818-821 10.1038/nchembio.1938
10. Jacoby, E.; Tresadern, G.; Bembenek, S.; Wroblowski, B.; Buyck, C.; Neefs, J. M.; Rassokhin, D.; Poncelet, A.; Hunt, J.; van Vlijmen, H. Extending kinome coverage by analysis of kinase inhibitor broad profiling data Drug Discovery Today 2015, 20, 652-658 10.1016/j.drudis.2015.01.002
11. Berman, H. M.; Bhat, T. N.; Bourne, P. E.; Feng, Z.; Gilliland, G.; Weissig, H.; Westbrook, J. The Protein Data Bank and the challenge of structural genomics Nat. Struct. Biol. 2000, 7 (Suppl) 957-959 10.1038/80734
12. Kinnings, S. L.; Jackson, R. M. Binding site similarity analysis for the functional classification of the protein kinase family J. Chem. Inf. Model. 2009, 49, 318-329 10.1021/ci800289y
13. McGregor, M. J. A pharmacophore map of small molecule protein kinase inhibitors J. Chem. Inf. Model. 2007, 47, 2374-2382 10.1021/ci700244t
14. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases Cell 2002, 109, 275-282 10.1016/S0092-8674(02)00741-9
15. Zhao, Z.; Wu, H.; Wang, L.; Liu, Y.; Knapp, S.; Liu, Q.; Gray, N. S. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 2014, 9, 1230-1241 10.1021/cb500129t
16. Furtmann, N.; Hu, Y.; Bajorath, J. Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analogues J. Med. Chem. 2015, 58, 252-264 10.1021/jm5009264
17. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39 10.1038/nrc2559
18. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 2007, 50, 409-424 10.1021/jm0608107
19. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis Bioinformatics 2010, 26, 198-204 10.1093/bioinformatics/btp650
20. Cui, J. J.; Tran-Dube, M.; Shen, H.; Nambu, M.; Kung, P. P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363 10.1021/jm2007613
21. Fabian, M. A.; Biggs, W. H., 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336 10.1038/nbt1068
22. Chuaqui, C.; Deng, Z.; Singh, J. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening J. Med. Chem. 2005, 48, 121-133 10.1021/jm049312t
23. Patricelli, M. P.; Nomanbhoy, T. K.; Wu, J.; Brown, H.; Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J. D.; Gray, N. S.; Kozarich, J. W. In situ kinase profiling reveals functionally relevant properties of native kinases Chem. Biol. 2011, 18, 699-710 10.1016/j.chembiol.2011.04.011
24. Shemon, A. N.; Heil, G. L.; Granovsky, A. E.; Clark, M. M.; McElheny, D.; Chimon, A.; Rosner, M. R.; Koide, S. Characterization of the Raf kinase inhibitory protein (RKIP) binding pocket: NMR-based screening identifies small-molecule ligands PLoS One 2010, 5, e10479 10.1371/journal.pone.0010479
25. Deng, Z.; Chuaqui, C.; Singh, J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions J. Med. Chem. 2004, 47, 337-344 10.1021/jm030331x
26. Witek, J.; Smusz, S.; Rataj, K.; Mordalski, S.; Bojarski, A. J. An application of machine learning methods to structural interaction fingerprints - a case study of kinase inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 580-585 10.1016/j.bmcl.2013.12.017
27. van Linden, O. P.; Kooistra, A. J.; Leurs, R.; de Esch, I. J.; de Graaf, C. KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space J. Med. Chem. 2014, 57, 249-277 10.1021/jm400378w
28. Bryant, D. H.; Moll, M.; Finn, P. W.; Kavraki, L. E. Combinatorial clustering of residue position subsets predicts inhibitor affinity across the human kinome PLoS Comput. Biol. 2013, 9, e1003087 10.1371/journal.pcbi.1003087
29. Cui, J. J. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress J. Med. Chem. 2014, 57, 4427-4453 10.1021/jm401427c
30. Punta, M.; Coggill, P. C.; Eberhardt, R. Y.; Mistry, J.; Tate, J.; Boursnell, C.; Pang, N.; Forslund, K.; Ceric, G.; Clements, J.; Heger, A.; Holm, L.; Sonnhammer, E. L.; Eddy, S. R.; Bateman, A.; Finn, R. D. The Pfam protein families database Nucleic Acids Res. 2012, 40, D290-301 10.1093/nar/gkr1065
31. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions J. Med. Chem. 2006, 49, 5912-5931 10.1021/jm050362n
32. Koes, D. R.; Camacho, C. J. Pharmer: efficient and exact pharmacophore search J. Chem. Inf. Model. 2011, 51, 1307-1314 10.1021/ci200097m
33. Mordalski, S.; Kosciolek, T.; Kristiansen, K.; Sylte, I.; Bojarski, A. J. Protein binding site analysis by means of structural interaction fingerprint patterns Bioorg. Med. Chem. Lett. 2011, 21, 6816-6819 10.1016/j.bmcl.2011.09.027
34. Marcou, G.; Rognan, D. Optimizing fragment and scaffold docking by use of molecular interaction fingerprints J. Chem. Inf. Model. 2007, 47, 195-207 10.1021/ci600342e
35. Mpamhanga, C. P.; Chen, B.; McLay, I. M.; Willett, P. Knowledge-based interaction fingerprint scoring: a simple method for improving the effectiveness of fast scoring functions J. Chem. Inf. Model. 2006, 46, 686-698 10.1021/ci050420d
36. Perez-Nueno, V. I.; Rabal, O.; Borrell, J. I.; Teixido, J. APIF: a new interaction fingerprint based on atom pairs and its application to virtual screening J. Chem. Inf. Model. 2009, 49, 1245-1260 10.1021/ci900043r
37. Wassermann, A. M.; Geppert, H.; Bajorath, J. Searching for target-selective compounds using different combinations of multiclass support vector machine ranking methods, kernel functions, and fingerprint descriptors J. Chem. Inf. Model. 2009, 49, 582-592 10.1021/ci800441c
38. Deng, Z.; Chuaqui, C.; Singh, J. Knowledge-based design of target-focused libraries using protein-ligand interaction constraints J. Med. Chem. 2006, 49, 490-500 10.1021/jm050381x
39. Chupakhin, V.; Marcou, G.; Baskin, I.; Varnek, A.; Rognan, D. Predicting ligand binding modes from neural networks trained on protein-ligand interaction fingerprints J. Chem. Inf. Model. 2013, 53, 763-772 10.1021/ci300200r
40. Xie, L.; Xie, L.; Bourne, P. E. A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery Bioinformatics 2009, 25, i305-312 10.1093/bioinformatics/btp220
41. Briedis, K. M.; Starr, A.; Bourne, P. E. Analysis of the human kinome using methods including fold recognition reveals two novel kinases PLoS One 2008, 3, e1597 10.1371/journal.pone.0001597
42. Xie, L.; Bourne, P. E. Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 5441-5446 10.1073/pnas.0704422105
43. Konc, J.; Janezic, D. Binding site comparison for function prediction and pharmaceutical discovery Curr. Opin. Struct. Biol. 2014, 25C, 34-39 10.1016/j.sbi.2013.11.012
44. Xie, L.; Ge, X.; Tan, H.; Xie, L.; Zhang, Y.; Hart, T.; Yang, X.; Bourne, P. E. Towards structural systems pharmacology to study complex diseases and personalized medicine PLoS Comput. Biol. 2014, 10, e1003554 10.1371/journal.pcbi.1003554
45. Nisius, B.; Sha, F.; Gohlke, H. Structure-based computational analysis of protein binding sites for function and druggability prediction J. Biotechnol. 2012, 159, 123-134 10.1016/j.jbiotec.2011.12.005
46. Xie, L.; Bourne, P. E. A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites BMC Bioinf. 2007, 8 (Suppl. 4) S9 10.1186/1471-2105-8-S4-S9
47. Xie, L.; Li, J.; Xie, L.; Bourne, P. E. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors PLoS Comput. Biol. 2009, 5, e1000387 10.1371/journal.pcbi.1000387
48. Chang, R. L.; Xie, L.; Xie, L.; Bourne, P. E.; Palsson, B. O. Drug off-target effects predicted using structural analysis in the context of a metabolic network model PLoS Comput. Biol. 2010, 6, e1000938 10.1371/journal.pcbi.1000938
49. Kinnings, S. L.; Liu, N.; Buchmeier, N.; Tonge, P. J.; Xie, L.; Bourne, P. E. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis PLoS Comput. Biol. 2009, 5, e1000423 10.1371/journal.pcbi.1000423
50. Xie, L.; Xie, L.; Bourne, P. E. Structure-based systems biology for analyzing off-target binding Curr. Opin. Struct. Biol. 2011, 21, 189-199 10.1016/j.sbi.2011.01.004
51. Garijo, D.; Kinnings, S.; Xie, L.; Xie, L.; Zhang, Y.; Bourne, P. E.; Gil, Y. Quantifying reproducibility in computational biology: the case of the tuberculosis drugome PLoS One 2013, 8, e80278 10.1371/journal.pone.0080278
52. Durrant, J. D.; Amaro, R. E.; Xie, L.; Urbaniak, M. D.; Ferguson, M. A.; Haapalainen, A.; Chen, Z.; Di Guilmi, A. M.; Wunder, F.; Bourne, P. E.; McCammon, J. A. A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology PLoS Comput. Biol. 2010, 6, e1000648 10.1371/journal.pcbi.1000648
53. Kinnings, S. L.; Xie, L.; Fung, K. H.; Jackson, R. M.; Xie, L.; Bourne, P. E. The Mycobacterium tuberculosis drugome and its polypharmacological implications PLoS Comput. Biol. 2010, 6, e1000976 10.1371/journal.pcbi.1000976
54. Xie, L.; Evangelidis, T.; Xie, L.; Bourne, P. E. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir PLoS Comput. Biol. 2011, 7, e1002037 10.1371/journal.pcbi.1002037
55. Xie, L.; Xie, L.; Kinnings, S. L.; Bourne, P. E. Novel computational approaches to polypharmacology as a means to define responses to individual drugs Annu. Rev. Pharmacol. Toxicol. 2012, 52, 361-379 10.1146/annurev-pharmtox-010611-134630
56. Kinnings, S. L.; Liu, N.; Tonge, P. J.; Jackson, R. M.; Xie, L.; Bourne, P. E. A machine learning-based method to improve docking scoring functions and its application to drug repurposing J. Chem. Inf. Model. 2011, 51, 408-419 10.1021/ci100369f
57. Chang, R. L.; Xie, L.; Bourne, P. E.; Palsson, B. O. Antibacterial mechanisms identified through structural systems pharmacology BMC Syst. Biol. 2013, 7, 102 10.1186/1752-0509-7-102
58. Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution Drug Discovery Today: Technol. 2004, 1, 337-341 10.1016/j.ddtec.2004.11.007
59. Klebe, G. Applying thermodynamic profiling in lead finding and optimization Nat. Rev. Drug Discovery 2015, 14, 95-110 10.1038/nrd4486
60. Constantine, K. L.; Mueller, L.; Metzler, W. J.; McDonnell, P. A.; Todderud, G.; Goldfarb, V.; Fan, Y.; Newitt, J. A.; Kiefer, S. E.; Gao, M.; Tortolani, D.; Vaccaro, W.; Tokarski, J. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects J. Med. Chem. 2008, 51, 6225-6229 10.1021/jm800747w
61. Chen, H.; Ma, J.; Li, W.; Eliseenkova, A. V.; Xu, C.; Neubert, T. A.; Miller, W. T.; Mohammadi, M. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases Mol. Cell 2007, 27, 717-730 10.1016/j.molcel.2007.06.028
62. Carter, T. A.; Wodicka, L. M.; Shah, N. P.; Velasco, A. M.; Fabian, M. A.; Treiber, D. K.; Milanov, Z. V.; Atteridge, C. E.; Biggs, W. H., 3rd; Edeen, P. T.; Floyd, M.; Ford, J. M.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Mehta, S. A.; Patel, H. K.; Pao, W.; Sawyers, C. L.; Varmus, H.; Zarrinkar, P. P.; Lockhart, D. J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 11011-11016 10.1073/pnas.0504952102
63. Foda, Z. H.; Seeliger, M. A. Kinase inhibitors: an allosteric add-on Nat. Chem. Biol. 2014, 10, 796-797 10.1038/nchembio.1630
64. Wu, P.; Nielsen, T. E.; Clausen, M. H. FDA-approved small-molecule kinase inhibitors Trends Pharmacol. Sci. 2015, 36, 422-439 10.1016/j.tips.2015.04.005
65. Cadranel, J.; Ruppert, A. M.; Beau-Faller, M.; Wislez, M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma Crit. Rev. Oncol. Hematol. 2013, 88, 477-493 10.1016/j.critrevonc.2013.06.009
66. Engel, J.; Richters, A.; Getlik, M.; Tomassi, S.; Keul, M.; Termathe, M.; Lategahn, J.; Becker, C.; Mayer-Wrangowski, S.; Grutter, C.; Uhlenbrock, N.; Krull, J.; Schaumann, N.; Eppmann, S.; Kibies, P.; Hoffgaard, F.; Heil, J.; Menninger, S.; Ortiz-Cuaran, S.; Heuckmann, J. M.; Tinnefeld, V.; Zahedi, R. P.; Sos, M. L.; Schultz-Fademrecht, C.; Thomas, R. K.; Kast, S. M.; Rauh, D. Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach J. Med. Chem. 2015, 58, 6844-6863 10.1021/acs.jmedchem.5b01082
67. Siegelin, M. D.; Borczuk, A. C. Epidermal growth factor receptor mutations in lung adenocarcinoma Lab. Invest. 2014, 94, 129-137 10.1038/labinvest.2013.147
68. Greig, S. L. Osimertinib: First Global Approval Drugs 2016, 76, 263-273 10.1007/s40265-015-0533-4
69. Walter, A. O.; Sjin, R. T.; Haringsma, H. J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovskiy, A.; Labenski, M.; Zhu, Z.; Wang, Z.; Sheets, M.; St Martin, T.; Karp, R.; van Kalken, D.; Chaturvedi, P.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W.; Lin, K.; Jaw-Tsai, S.; Raponi, M.; Van Dyke, T.; Etter, J.; Weaver, Z.; Pao, W.; Singh, J.; Simmons, A. D.; Harding, T. C.; Allen, A. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discovery 2013, 3, 1404-1415 10.1158/2159-8290.CD-13-0314
70. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074 10.1038/nature08622
71. Adams, J. A. Kinetic and catalytic mechanisms of protein kinases Chem. Rev. 2001, 101, 2271-2290 10.1021/cr000230w
72. Bollag, G.; Tsai, J.; Zhang, J.; Zhang, C.; Ibrahim, P.; Nolop, K.; Hirth, P. Vemurafenib: the first drug approved for BRAF-mutant cancer Nat. Rev. Drug Discovery 2012, 11, 873-886 10.1038/nrd3847
73. Shaw, A. T.; Kim, D. W.; Mehra, R.; Tan, D. S.; Felip, E.; Chow, L. Q.; Camidge, D. R.; Vansteenkiste, J.; Sharma, S.; De Pas, T.; Riely, G. J.; Solomon, B. J.; Wolf, J.; Thomas, M.; Schuler, M.; Liu, G.; Santoro, A.; Lau, Y. Y.; Goldwasser, M.; Boral, A. L.; Engelman, J. A. Ceritinib in ALK-rearranged non-small-cell lung cancer N. Engl. J. Med. 2014, 370, 1189-1197 10.1056/NEJMoa1311107
74. Fabbro, D. 25 years of small molecular weight kinase inhibitors: potentials and limitations Mol. Pharmacol. 2015, 87, 766-775 10.1124/mol.114.095489
75. Ohren, J. F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W. T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J.; Dudley, D. T.; Leung, I. K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C. A. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat. Struct. Mol. Biol. 2004, 11, 1192-1197 10.1038/nsmb859
76. Huang, W. S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J. Med. Chem. 2010, 53, 4701-4719 10.1021/jm100395q
77. O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W. S.; Xu, Q.; Metcalf, C. A., 3rd; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W.; Druker, B. J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 2009, 16, 401-412 10.1016/j.ccr.2009.09.028
78. Solca, F.; Dahl, G.; Zoephel, A.; Bader, G.; Sanderson, M.; Klein, C.; Kraemer, O.; Himmelsbach, F.; Haaksma, E.; Adolf, G. R. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J. Pharmacol. Exp. Ther. 2012, 343, 342-350 10.1124/jpet.112.197756
79. Pan, Z.; Scheerens, H.; Li, S. J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase ChemMedChem 2007, 2, 58-61 10.1002/cmdc.200600221
80. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27, 4702-4711 10.1038/onc.2008.109
81. Food and Drug Administration (FDA) approved drug products. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed Dec 21, 2015).
82. Garuti, L.; Roberti, M.; Bottegoni, G. Irreversible protein kinase inhibitors Curr. Med. Chem. 2011, 18, 2981-2994 10.2174/092986711796391705
83. Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 2013, 20, 146-159 10.1016/j.chembiol.2012.12.006
84. Mi, Y. J.; Liang, Y. J.; Huang, H. B.; Zhao, H. Y.; Wu, C. P.; Wang, F.; Tao, L. Y.; Zhang, C. Z.; Dai, C. L.; Tiwari, A. K.; Ma, X. X.; To, K. K.; Ambudkar, S. V.; Chen, Z. S.; Fu, L. W. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Cancer Res. 2010, 70, 7981-7991 10.1158/0008-5472.CAN-10-0111
85. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 10.1093/nar/28.1.235
86. Salama, A. K.; Kim, K. B. Trametinib (GSK1120212) in the treatment of melanoma Expert Opin. Pharmacother. 2013, 14, 619-627 10.1517/14656566.2013.770475
87. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364 10.1038/nchembio799
88. McTigue, M.; Murray, B. W.; Chen, J. H.; Deng, Y. L.; Solowiej, J.; Kania, R. S. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 18281-18289 10.1073/pnas.1207759109
89. Pemovska, T.; Johnson, E.; Kontro, M.; Repasky, G. A.; Chen, J.; Wells, P.; Cronin, C. N.; McTigue, M.; Kallioniemi, O.; Porkka, K.; Murray, B. W.; Wennerberg, K. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation Nature 2015, 519, 102-105 10.1038/nature14119
90. Harvard Medical School (HMS) LINCS Database. http://lincs.hms.harvard.edu/explore/ (accessed Sep 22, 2015).
91. Shmelkov, E.; Grigoryan, A.; Swetnam, J.; Xin, J.; Tivon, D.; Shmelkov, S. V.; Cardozo, T. Historeceptomic fingerprints for drug-like compounds Front. Physiol. 2015, 6, 371 10.3389/fphys.2015.00371
92. UniProt Consortium Update on activities at the Universal Protein Resource (UniProt) in 2013 Nucleic Acids Res. 2013, 41, D43-D47 10.1093/nar/gks1068
93. UniProt Consortium. Human and mouse protein kinases: classification and index. http://www.uniprot.org/docs/pkinfam.txt (accessed May 15, 2015).
94. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm J. Mol. Biol. 1996, 261, 470-489 10.1006/jmbi.1996.0477
95. Kellenberger, E.; Muller, P.; Schalon, C.; Bret, G.; Foata, N.; Rognan, D. sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank J. Chem. Inf. Model. 2006, 46, 717-727 10.1021/ci050372x
96. Radifar, M.; Yuniarti, N.; Istyastono, E. P. PyPLIF: python-based protein-ligand fnteraction fingerprinting Bioinformatics 2013, 9, 325-328 10.6026/97320630009325
97. Uchikoga, N.; Hirokawa, T. Analysis of protein-protein docking decoys using interaction fingerprints: application to the reconstruction of CaM-ligand complexes BMC Bioinf. 2010, 11, 236 10.1186/1471-2105-11-236
98. Jaccard, P. The distribution of the flora in the alpine zone New Phytol. 1912, 11, 37-50 10.1111/j.1469-8137.1912.tb05611.x
99. Hartigan, J. A.; Wong, M. A. Algorithm AS 136: A K-means clustering algorithm Appl. Stat. 1979, 28, 100-108 10.2307/2346830
100. Rogers, D.; Hahn, M. Extended-connectivity fingerprints J. Chem. Inf. Model. 2010, 50, 742-754 10.1021/ci100050t
101. Hu, Y.; Lounkine, E.; Bajorath, J. Improving the search performance of extended connectivity fingerprints through activity-oriented feature filtering and application of a bit-density-dependent similarity function ChemMedChem 2009, 4, 540-548 10.1002/cmdc.200800408
102. JChem Base was used for structure searching and chemical database access and management. JChem 6.2.0; ChemAxon, 2014; http://www.chemaxon.com.
103. Weill, N.; Rognan, D. Alignment-free ultra-high-throughput comparison of druggable protein-ligand binding sites J. Chem. Inf. Model. 2010, 50, 123-135 10.1021/ci900349y